Proteogenomics connects somatic mutations to signalling in breast cancer.
Mertins, Philipp; Mani, D R; Ruggles, Kelly V; Gillette, Michael A; Clauser, Karl R; Wang, Pei; Wang, Xianlong; Qiao, Jana W; Cao, Song; Petralia, Francesca; Kawaler, Emily; Mundt, Filip; Krug, Karsten; Tu, Zhidong; Lei, Jonathan T; Gatza, Michael L; Wilkerson, Matthew; Perou, Charles M; Yellapantula, Venkata; Huang, Kuan-lin; Lin, Chenwei; McLellan, Michael D; Yan, Ping; Davies, Sherri R; Townsend, R Reid; Skates, Steven J; Wang, Jing; Zhang, Bing; Kinsinger, Christopher R; Mesri, Mehdi; Rodriguez, Henry; Ding, Li; Paulovich, Amanda G; Fenyö, David; Ellis, Matthew J; Carr, Steven A.
; 534(7605): 55-62, 2016 06 02.
Artigo em Inglês | MEDLINE | ID: mdl-27251275
Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.
ErbB2-driven breast cancer cell invasion depends on a complex signaling network activating myeloid zinc finger-1-dependent cathepsin B expression.
The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis.
A complex containing LPP and α-actinin mediates TGFß-induced migration and invasion of ErbB2-expressing breast cancer cells.
Coamplification of <i>miR-4728</i> protects <i>HER2</i>-amplified breast cancers from targeted therapy.
Trials and tribulations.
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer.
Genome wide proteomics of ERBB2 and EGFR and other oncogenic pathways in inflammatory breast cancer.
Regulation of tamoxifen sensitivity by a PAK1-EBP1 signalling pathway in breast cancer.
Parallel visualization of multiple protein complexes in individual cells in tumor tissue.